Boston Scientific Corp. vs. Bioventus Inc. Class A Common Stock
Boston Scientific Corp. (BSX) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| BSX | BVS | |
|---|---|---|
| Market Cap | $75.11 billion | $1.20 billion |
| Revenue (TTM) | $21.00 billion | $581.85 million |
| Net Income (TTM) | $3.67 billion | $61.48 million |
BSX leads on 3 of 3 size & scale factors.
Valuation
| BSX | BVS | |
|---|---|---|
| P/E Ratio | 20.98 | 18.52 |
| Price / Book | 2.98 | 4.32 |
| Price / Sales | 3.58 | 2.06 |
BVS leads on 2 of 3 valuation factors.
Profitability
| BSX | BVS | |
|---|---|---|
| Net Margin | 17.47% | 10.57% |
| Return on Equity | 14.58% | 22.16% |
BSX and BVS split the profitability factors evenly.
Risk & Sentiment
| BSX | BVS | |
|---|---|---|
| Short Interest | 0.72% | 0.78% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, BVS overview, BVS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.